Results 121 to 130 of about 81,525 (242)

Improving drug identification in overdose death surveillance by using clinical natural language processing models

Journal of Forensic Sciences, EarlyView.
Abstract The rising rate of drug‐related deaths in the United States, largely driven by fentanyl, requires timely and accurate surveillance. However, critical overdose data are often buried in free‐text coroner reports, leading to delays and information loss when coded into ICD (International Classification of Disease)‐10 classifications.
Arthur J. Funnell, Panayiotis Petousis, Fabrice Harel‐Canada, Ruby Romero, Alex A. T. Bui, Adam Koncsol, Hritika Chaturvedi, Chelsea Shover, David Goodman‐Meza   +8 more
wiley   +1 more source

Expanding buprenorphine prescribing in primary care: a qualitative study of the experiences of primary care providers and nurse care managers participating in the New York City buprenorphine nurse care manager initiative

Harm Reduction Journal
Background Improving access to and retention in evidence-based treatment for opioid use disorder, including buprenorphine, is a critical response to the opioid overdose crisis.
Elodie C. Warren, Nisha Beharie, Marissa Kaplan-Dobbs, Asmara Tesfaye Rogoza, Alex Harocopos   +4 more
doaj   +1 more source

A state-level study of opioid use disorder treatment access and neonatal abstinence syndrome [PDF]

, 2019
Background Adult opioid use and neonatal abstinence syndrome (NAS) are growing public health problems in the United States (U.S.). Our objective was to determine how opioid use disorder treatment access impacts the relationship between adult opioid use ...
Abbinanti, Kassie, Krist, Alex H., Pecsok, James, Sabo, Roy T., Tong, Sebastian T., Wolf, Elizabeth R., Woolf, Steven H.   +6 more
core   +1 more source

Trajectories of medication for opioid use disorder and their impact on HIV testing among people who inject drugs in India: A longitudinal assessment of clinic‐based data

Addiction, Volume 120, Issue 4, Page 745-755, April 2025.
Abstract Aims The aim of this study was to identify longitudinal trajectories of medication for opioid use disorder (MOUD) use throughout 1 year following MOUD initiation and to examine the association of trajectory membership with HIV testing among people who inject drugs in India.
Allison M. McFall, Lakshmi Ganapathi, Mihili P. Gunaratne, Aylur K. Srikrishnan, Conjeevaram K. Vasudevan, Santhanam Anand, Sunil S. Solomon, Shruti H. Mehta, Gregory M. Lucas   +8 more
wiley   +1 more source

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

Donepezil reverses buprenorphine-induced central respiratory depression in anesthetized rabbits

Biological Research, 2009
Buprenorphine is a mixed opioid receptor agonist-antagonist used in acute and chronic pain management. Although this agent's analgesic effect increases in a dose-dependent manner, buprenorphine-induced respiratory depression shows a marked ceiling effect
SHIGEKI SAKURABA, MIKI TSUJITA, HIROFUMI ARISAKA, JUNZO TAKEDA, KAZUICHI YOSHIDA, SHUN-ICHI KUWANA   +5 more
doaj  

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

A cost–benefit analysis of the implementation and scale‐up of harm reduction interventions in the Australian Capital Territory

Addiction, EarlyView.
Abstract Background and aims Harm reduction interventions aim to reduce negative consequences of drug use. We aimed to estimate the cost, health impact and economic benefits of current, expanded and new harm reduction interventions for people who use drugs in the Australian Capital Territory.
Anna L. Bowring, Tom Tidhar, Anna Olsen, Christopher Bailie, Kelvin Burke, Rowan Martin‐Hughes, Helen Keane, Paul Dietze, Nick Scott   +8 more
wiley   +1 more source

The association of methadone use with physical function and frailty among persons who inject drugs

Addiction, EarlyView.
Abstract Background and Aims Persons who inject drugs (PWID) experience a high burden of early‐onset frailty, primarily due to multifactorial causes such as infections (human immunodeficiency virus [HIV], hepatitis C virus [HCV]), substance use, and polypharmacy.
Grace L. Kulik, Hsing‐Yu Hsu, Jacqueline Rudolph, Yutong Jiang, Kristine M. Erlandson, Damani A. Piggott, Shruti Mehta, Jeremy D. Walston, Gregory Kirk, Todd T. Brown, Jing Sun   +10 more
wiley   +1 more source

Addiction‐related problems in Japan: A regional perspective

Addiction, EarlyView.
Abstract Japan's addiction landscape appears paradoxical. The lifetime use of illicit drugs is among the lowest in Organisation for Economic Cooperation and Development countries, but harm from alcohol, tobacco, and gambling ranks among the world's highest.
Soichiro Ide, Yoko Nishitani, Masahiko Sumitani, Masabumi Minami, Tadashi Isa, Masako Iseki, Michiko Ohkura, Hitoshi Okamoto, Tetsuro Kikuchi, Yuko Sekino, Hidehiko Takahashi, Kenji Takeuchi, Atsumi Nitta, Takeshi Honjo, Hiroshi Matsumoto, Tsuyoshi Miyakawa, Toshiya Murai, Toshihiko Matsumoto, Kazuyuki Nakagome, Kazutaka Ikeda   +19 more
wiley   +1 more source